ClinicalTrials.gg
RecruitingNCT07502664DEFINE-IRDUpdated Mar 31, 2026

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

An observational study in Retinitis Pigmentosa, Stargardt Macular Dystrophy and Stargardt Disease, sponsored by Ray Therapeutics, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.

Sponsored by Ray Therapeutics, Inc. · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 119 studies in Retinitis Pigmentosa with a site in United States — 20 open to participants now, 43 under way, 6 of them phase 3. Retinitis Pigmentosa · United States.

Planned enrollment
32nd of 38
25 · median 73
Started
2026
with 4 others
Observational
39 of 119
11 open now
Primary completion
2027-02
later than 14 of 41 live
Registered
117th of 119
by date
Lead sponsor
4 of 119
Ray Therapeutics, Inc.

Among the 119 studies in Retinitis Pigmentosa with a site in United States, this one is the 32nd largest by planned enrollment of the 38 observational ones that give a count, is one of 5 that started in 2026, is one of 39 observational ones, reaches primary completion later than 14 of the 41 other live ones, and was the 117th registered.

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

Browse Retinitis Pigmentosa studies →

Open to participants now

20 of the 119 studies in Retinitis Pigmentosa with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Retinitis Pigmentosa studies recruiting now, 38 (76%) set no upper age limit and 6 (12%) stop at 75 or younger; 16 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 119 studies in Retinitis Pigmentosa with a site in United States, or all of them as a file.
02

Study summary

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.

The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.

The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Read the detailed description

This observational, non-interventional study is designed to assess both the operational feasibility and the measurement properties of selected visual function assessments in this population. The study will emphasize outcome measures that are sensitive to peripheral visual function and that reflect real-world functional abilities, including spatial orientation, mobility, and wayfinding.

03

Conditions studied

  • Retinitis Pigmentosa
  • Stargardt Macular Dystrophy
  • Stargardt Disease
  • Geographic Atrophy From Age-related Macular Degeneration
  • X-linked Retinoschisis
  • Retinal Dystrophies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with moderate to profound vision impairment diagnosed with retinitis pigmentosa or other retinal dystrophies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records
  • Best-corrected visual acuity between 20/200 to HM in at least one eye.
  • Reasonably fluent in English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment, memory loss or dementia sufficient in severity to preclude or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
  • Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
  • Current pregnancy as reported by patient
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No

Groups and cohorts

  • Retinitis Pigmentosa

    Up to 25 patients with Retinitis Pigmentosa

  • Other Retinal Dystrophies

    Up to 25 patients with Other Retinal Dystrophies

06

What researchers measure

Primary outcomes

  1. Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments

    Determining how many patients in the visual range 20/200 - HM (depending upon indication) can perform specific tests of visual function with a measurable score.

    Time frame: 3 months

Secondary outcomes

  1. To quantify patient-based measurement properties of each test modality (for the purposes of endpoint qualification)

    Test-rest reliability on the same visit or on two different testing sessions on different days including determination of significant learning effects of other scoring variables that impact variability.

    Time frame: 2 years

  2. To quantify assessor-based measurement properties of each test modality (for the purposes of endpoint qualification)

    Intra- and inter-grader variability for scoring of tests by test graders/raters. Assessments incorporating independent graders/raters will be assessed for within session and across session scoring reliability to ensure consistent methods.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Mar 31, 2026
StartActual
Feb 19, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07502664
Lead sponsor
Ray Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Feb 19, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 31, 2026

Study contacts

Reem Jaber, MS, CGC
Contact
info@vr-ai.com
949-264-3793

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion